MCK241004P495000
- 13.31
- 0.000.00%
McKesson Newsroom
Argus Research Maintains McKesson(MCK.US) With Buy Rating, Announces Target Price $570
Argus Adjusts Price Target on McKesson to $570 From $640
Here's Why McKesson (MCK) Is a Strong Value Stock
Cramer's Lightning Round: McKesson Is a Buy
McKesson Price Target Raised to $86 From $85 at Jefferies
Sorenson Names Seasoned Leader as Global Chief Information and Technology Officer
McKesson Launches InspiroGene, a Dedicated Business to Guide and Support the Commercialization of Cell and Gene Therapies
Why Drug Distributors Are Buying Cancer Specialists -- Heard on the Street -- WSJ
McKesson (MCK) Stock Sinks As Market Gains: Here's Why
Is McKesson Corporation (MCK) the Best Stock To Buy Right Now According To Billionaire Cliff Asness?
Is Most-Watched Stock McKesson Corporation (MCK) Worth Betting on Now?
Here's How Much You Would Have Made Owning McKesson Stock In The Last 15 Years
Deutsche Bank Maintains McKesson(MCK.US) With Buy Rating, Raises Target Price to $579
McKesson Price Target Lowered to $579 From $623 at Deutsche Bank
McKesson Currently Down Seven Consecutive Days, on Pace for Longest Losing Streak Since July 2023 -- Data Talk
Buy Rating Affirmed: McKesson's Long-term Growth Strategy Balances Short-term Earnings Concerns
Baird: mckesson (MCK.US) held an "abnormal" seller event and lowered the target price to $531.
Baird downgraded medical distributor mckesson's rating from outperform large cap to neutral on Tuesday and lowered its target stock price from $603 to $531.
Top Gap Ups and Downs on Tuesday: V, MUFG, SMFG and More
Stock Of The Day: Has McKesson Found Its Bottom And Will It Bounce Back?
McKesson Cut to Neutral at Baird on "Unusual" Sell Side Event